So, the natural question for Acrivon Therapeutics (NASDAQ:ACRV) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) ...

Agenus Inc. , a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, ...

Novartis has announced that it will be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for ...

DeepL, a leading global Language AI company, today unveiled its latest white paper, "The language revolution: how AI improves the way businesses communicate." Based on findings from a new DeepL survey ...

Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

These are the most popular stories from the Financial Times. These stories have not been verified and we cannot vouch their accuracy.